Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 13/20 | 0.80 |
| ▸ | RARB | P10826 | 12/20 | 0.80 |
| ▸ | RARG | P13631 | 11/20 | 0.80 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 1/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | BLVRB | P30043 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152370 | 0.85 | RARB (0.91) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL7755634 | 0.84 | RARA (0.57) | RARARARBRARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL29373818 | 0.83 | RARB (1.00) | RARARARBRARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL36207 | 0.83 | RARB (1.00) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL8461304 | 0.82 | RARA (0.78) | RARARARBRARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL21055743 | 0.82 | RARB (0.97) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL8461601 | 0.81 | CYP26A1 (0.82) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL30590581 | 0.81 | RARA (1.00) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL1615110 | 0.78 | RARA (0.80) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL19560600 | 0.78 | RARA (0.80) | RARARARBRARGCYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876330-B1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2001-03-28 | — | — | EP | claimed |
| EP-0876330-A1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-11-11 | — | — | EP | claimed |
| WO-1997019052-A1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | claimed |
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534544-B1 | Administering retinoid compound as anticarcinogenic and antitumor agents; side effect reduction | ALLERGAN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | ALLERGAN SALES, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6342602-B1 | BIND SPECIFICALLY OR SELECTIVELY TO RAR-ALPHA RECEPTORS | ALLERGAN SALES, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-0876330-B1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6124455-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6034244-A | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTICANCER AGENT | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5856490-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN (US) | 1999-01-05 | — | — | US | disclosed |
| US-5675024-A | RETINOID RECEPTOR AGONISTS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | RARG, RARA, RARB | RARA 2/4885RARB 3/4885RARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.